(Submitted for publication June 13, 1955; accepted August 31, 1955) Conley and Hartmann (1, 2) have reported the existence of a disorder of blood clotting in two patients with systemic lupus erythematosus. In both cases there were severe hemorrhagic symptoms associated with prolongation of the clotting time and the presence of a substance interfering with the interaction of thromboplastin and prothrombin.
Previous studies in this laboratory (3) had suggested that the L. E. cell factor required thromboplastin or some component thereof, in order to act on leukocytes.
A possible relationship between these two sets of data suggested itself: the L. E. cell factor, reacting in some way with thromboplastin, could inhibit thromboplastin in turn from reacting with prothrombin. If this hypothesis were valid, every blood containing the L. E. cell factor should show impaired thromboplastin function. The clotting disorder described might thus be a characteristic feature of systemic lupus.
To test this hypothesis, a systematic survey of blood coagulation in every available patient with systemic lupus erythematosus was undertaken.
MATERIALS AND METHODS
Forty-three consecutive patients with systemic lupus erythematosus were studied. Most of these were from the Wards and the Out-Patient Department of The Mount Sinai Hospital; some were private patients or patients in other hospitals.3 1 Supported by a grant (A-221) from the U. S. Public Health Service, National Institute of Arthritis and Metabolic Diseases, and the A. A. List and Anna Ruth Lowenberg Funds. 2 Presented (in part) at the Annual Meeting of the Eastern Section of the American Federation for Clinical Research, Boston, January, 1954. 8 We are indebted to S. R. Karelitz, M. Levitt, S. Miller, B. S. Oppenheimer, and N. Rosenthal and to the staffs of the Brooklyn Regional Center of the Veterans' Administration, Harlem Hospital, Jewish Memorial Hospital and the New York Hospital for the opportunity to study individual patients included in this study.
All procedures were performed on fresh blood drawn through a clean venipuncture into siliconized equipment.
The following studies were performed on each patient: 1) L. E. cell preparation: In each patient the L. E. cell was demonstrated by the clotted blood technique (4) or by incubation of serum with washed normal leukocytes (5) .
2) Platelet counts were done by the method of Ottenberg and Rosenthal (6) .
3) Whole blood clotting times were done by the modified Lee-White method using one tube of eleven mm. diameter with incubation at 370 C. 4 ) Plasma clotting times were measured by the method of Quick (7) , using both platelet-rich and platelet-poor plasmas. In every case platelet-rich plasma was obtained by sedimentation of red cells without centrifugation. Platelet-poor plasma was prepared by centrifugation in silicone-coated tubes for 30 minutes at 4,500 rpm., in the Sorvall Angle Centrifuge at room temperature. 5) Prothrombin times were performed by the onestage method of Quick (7) .
6) The residual serum prothrombin activity was determined by the method of Stefanini and Crosby (8) .
Where abnormalities were found, some or all of the following tests were performed:
1) The presence of an anticoagulant was shown by the ability of the blood or plasma to prolong the coagulation time of normal blood or plasma.
2) Thrombin generation tests were done by a modification of the method of Pitney and Dacie (9): a) One ml. of platelet-rich plasma obtained without centrifugation was added to 1 ml. of 0.025 M CaCl2 and 0.25 ml. of normal saline or test material in a glass tube. b) The reaction mixture was allowed to incubate at 370 C. and at 1-minute intervals 0. 3) Thromboplastin dilution studies were performed by 6) Fractionation of plasma was carried out by the making serial dilutions of rabbit brain thromboplastin method of Svensson (10) . The identity of plasma frac-(Difco) in saline. One-tenth ml. of each dilution was tions obtained was confirmed by filter paper electroadded in turn to 0.1 ml. of test plasma and 0.1 ml. of phoresis. 0.025 M CaCl, and clotting times measured as in the 7) Thromboplastin generation tests were carried out Quick prothrombin test.
according to the method of Biggs and Douglas (11), 4) The thrombin dilution tests were done by making modified in that barium-sulfate-adsorbed plasma was used serial dilutions of Topical Thrombin (Parke-Davis) as a source of anti-hemophilic globulin instead of aluminafrom 100 to 0.5 N.I.H. units per ml. One-tenth ml. of treated plasma. each dilution was then added in turn to 0.1 ml. of test plasma and clotting time measured.
RESULTS

5) Protamine titrations were performed by making
Of the forty-three patients with systemic lupus serial dilutions of protamine sulfate, adding platelet-rich oxalated plasma and 0.025 M CaCl2, and measuring erythematosus who were studied, thirty-one clotting time.
showed no abnormality of the coagulation mecha- Normal results: 1) Peak at 4 to 6 min.
2) Thrombin generated at maximum 2 to 8.7 units.
3) Measurable amounts appeared at 2 minutes in every case and fell off rapidly by 10 minutes.
* Patients in whom an anticoagulant was demonstrated (see Table III )., nism. The results obtained in the remaining twelve patients are discussed below.
1) Whole Blood Clotting Time (Table I) In four patients the whole blood clotting time was definitely prolonged. In the remaining eight it was normal or borderline.
2) Plasma Clotting Time (Table I) The clotting time of recalcified plasma prepared from oxalated whole blood without centrifugation was prolonged in six.
However, when the plasma was made plateletpoor the recalcification time became prolonged in three additional patients. (Table I) The prothrombin time of eight of the twelve patients was prolonged. In each case having a prolonged prothrombin time, mixture with equal parts of normal plasma failed to yield complete correction of the abnormality. (Table I) All patients had normal consumption of prothrombin with the exception of R.S., who at the time the test was performed had a platelet count of 8,000/mm3. (Table I) The platelet count was markedly diminished in two patients, moderately so in five, and normal in five. (Table II, Figure   1 )
3) Prothrombin Times
4) Serum Prothrombin Activity
5) Platelets
6) Thrombin Generation Test
The thrombin generation test was performed on ten of the twelve patients, and on 50 control subjects. In three of the patients the formation of thrombin was delayed and the maxumum amount generated was below normal. In five others, while there was a delay in thrombin formation, the maximum amount generated was normal. In the remaining two patients, the thrombin generation curves were low normal.
In patient R. S., who had a severe thrombocyto- penia, thrombin generation was both delayed and impaired. Figure 2 demonstrates the partial correction of thrombin generation by the addition of normal platelet-rich plasma. A mixture containing only 20 per cent of R. S. plasma delayed thrombin generation in the normal plasma although the peak of formation of thrombin was not materially decreased. (Table   III) In all patients in whom a prolonged whole blood or plasma clotting time was observed, a circulat-ing anticoagulant was demonstrated by mixtures with normal whole blood or plasma. (Table IV, Figure   3 )
7) Demonstration of the Anticoagulant
8) Thromboplastin Dilutions
Thromboplastin dilution studies were performed on seventy-five normal subjects and gave values shown in the shaded area of this chart. In eleven of the twelve patients under discussion there was definite prolongation of the clotting time of plasma to which diluted thromboplastin was added. Values within the normal range were obtained from one patient in this group.
9) Thrombin Dilutions
In the same seven patients in whom the anticoagulant was demonstrated, thrombin dilution studies were carried out. Abnormal findings were present in three patients. (M. M., R. S., and B. L.) When the plasma of M. M., and R. S., were stored at 4°C. overnight, their antithrombin activity had disappeared, although anticoagulant activity was unimpaired. In the case of B. L., however, both anticoagulant and anti-thrombin activity had disappeared after overnight refrigeration.
10) Protamine Titration
This procedure was carried out on three plasmas showing anticoagulant activity. No heparin-like activity could be demonstrated. Table III ).
t Equals one-stage prothrombin time. 
11) Thromboplastin Generation
It will be noted from Table I and Table III that in patient J. I. in whom a prolonged clotting time and anticoagulant were demonstrated the thromboplastin dilution tests were within normal limits. When a thromboplastin generation test was performed using J. I.'s plasma, it showed impaired formation of thromboplastin. When the same test was performed on plasma of E. L., and M. M., who were among the most severely affected in this group, the generation of thromboplastin was within normal limits.
12) Plasma Fractionation
Plasma from patient E. L. was found to have the highest titer of anticoagulant activity in this series (1: 128).4 Aliquots of fresh plasma from this patient were fractionated by the method of Svensson (10) , after which whole plasma and each of the fractions obtained were tested for anti- 4 Plasma from E. L., when diluted with normal plasma to a final concentration of 1: 128, showed significant prolongation of recalcification time as compared with the normal plasma alone. coagulant activity. The fraction precipitated between 25 and 33% per cent saturation of (NH,)2 SO4 was the only active one. This fraction showed mainly gamma globulin motility in paper electrophoresis. DISCUSSION From these data it would seem that seven of the forty-three patients studied showed distinct abnormality of blood coagulation. This abnormality (Table I ) took roughly the same form in all seven, although it varied in degree. Marked delay of clotting of platelet-poor plasma was found in all. Most had some prolongation of whole blood coagulation time and of one-stage prothrombin time.
Although all but one (R. S.) showed apparently normal prothrombin conversion at the end of one hour, thrombin generation tests (Table II, Figure 1) . showed that a delay in conversion of prothrombin was present in all of the six so studied.
Plasma mixture experiments performed on the bloods of these patients showed the presence of circulating anticoagulants in all seven. It then became important to demonstrate the sites of action of these anticoagulants. In the schema of blood coagulation, three major reactions occur: 1) The formation of thromboplastin by interaction of platelets, calcium and plasma thromboplastin precursor substances; 2) the conversion of prothrombin to thrombin by the action of thromboplastin in the presence of the two accelerator substances; and 3) the formation of fibrin from fibrinogen under the influence of thrombin. In only the third of these reactions is there any extensive knowledge of either the kinetics of the reaction or the nature of the reacting substances. Nevertheless it is possible to detect gross interference with any one of the three reactions.
Addition of varying amounts of pre-formed thrombin to a test plasma by-passes the first two reactions. Marked delay in fibrin formation (by comparison with normal controls and in the presence of normal fibrinogen concentrations) indicates the presence of a substance which inhibits the action of thrombin.
Similarly, addition of varying amounts of preformed thromboplastin to a test plasma by-passes the first reaction. A plasma which demonstrated delayed fibrin formation under the conditions of this test may contain a substance interfering with either the second or the third reaction (if it can be shown that the defect is not due to a deficiency of any necessary substances).
By means of the thromboplastin generation test of Biggs and Douglas (11) , it is possible to detect the presence of a substance interfering with the formation of thromboplastin-the first reaction of the clotting process. In this test, prothrombinfree plasma (containing some of the plasma thromboplastin precursors, but not all) is incubated with platelets and serum (containing the remaining plasma thromboplastin precursors) in the presence of calcium. At stated intervals, aliquots are removed from the reaction mixture and tested for thromboplastin potency against normal plasma. In our studies normal platelets were employed, with serum and barium-sulfate-treated plasma from the patient in question. It was possible so to manipulate the concentrations of the reagents that the critical dilution of the anticoagulant (determined previously by mixture with normal plasma) was not exceeded in the first reaction mixture, but was exceeded in the second stage of the test. In this way, although the end point of this, as of all coagulation tests, is the production of fibrin, the activity of the anticoagulant could be confined to the first coagulation reaction-the formation of thromboplastin.
The foregoing paragraphs are admittedly oversimplifications. The "thromboplastin" measured in the thromboplastin generation test of Biggs and Douglas is not the same substance as the active ingredient of dehydrated rabbit brain. And addition of thrombin to plasma does not completely by-pass the first stages of coagulation: Alexander, Goldstein, Rich, Le Bolloc'h, Diamond, and Borges (12) have shown that the anti-hemophilic factor of plasma is consumed when this reaction occurs. Nevertheless, this schema, in a crude way, allows one to characterize a circulating anticoagulant.
In six of the seven patients with circulating anticoagulants, increased resistance to the action of thromboplastin was noted (Table IV) . One (J. I., Figure 3 ) showed insufficient evidence of this type of anti-thromboplastic activity. However, thromboplastin generation in her blood was definitely impaired, whereas thromboplastin generation of two of the most severely affected of the other patients (E. L. and M. M.) was within normal limits. On the other hand, increased anti-thrombin activity was demonstrated on only one patient (B. L.) of the seven. In this patient the anti-thrombin could have been responsible for all the abnormal findings.
In the case of patient J. I., then, the circulating anticoagulant apparently acted to prevent the formation of thromboplastin. In patients E. L., R. S., M. M., J. H., and B. V., the anticoagulants seemed to act to prevent the action of thromboplastin with prothrombin. In patient B. L., there was in addition evidence of interference with the action of thrombin.5
In addition to these patients, five of the remaining showed minor coagulation defects (Tables I and II, Figure 1) , and an increased resistance to the action of thromboplastin. (Table IV, Figure  3 ). None of these five had sufficient prolongation of clotting times of blood or plasma to allow proof of the existence of circulating anticoagulants. However it seems probable that the abnormalities observed in their blood specimens were due to lesser degrees of the same disorder found in the seven cases already discussed.
Of forty-three patients studied, twelve showed disorders of coagulation other than thrombocytopenia. One of these had a circulating anticoagulant active in the first stage; eleven showed interference with the action of thromboplastin (second stage). Of these, the anticoagulant activity may have been due to an anti-thrombin in one.
Clinical significance
Only four of the forty-three patients studied had ever had hemorrhagic manifestations. All of these four had severe thrombocytopenia at one time during the course of their disease. The relationships among thrombocytopenia, anticoagulant and bleeding in these patients are summarized in Table V . In only one patient (E. L.) was there a hemorrhagic diathesis which could be attributed unequivocally to the presence of circulating anticoagulant. Thus the clotting disorder observed has a low order of clinical significance insofar as bleeding manifestations are concerned.
It would appear to be somewhat more important as confirmatory evidence of the diagnosis of systemic lupus erythematosus. Anomalies of clotting strictly comparable to these found in 10 of these patients have not been observed with any considerable frequency in any other disease. The literature contains reports of 33 cases of naturally occurring circulating anticoagulants. These fall into three large groups as follows:
1. Patients with congenital hemophilia who become resistant to therapy and are found to have developed an ability to neutralize anti-hemophilic globulin.
2. Young women (usually post-partum) who develop a hemorrhagic diathesis associated with prolonged clotting time and the presence of a circulating substance which can neutralize antihemophilic globulin.
3. A heterogeneous group of patients with acquired hemorrhagic tendencies, in whom the circulating anticoagulants appear to operate at different levels of the clotting mechanism.
Among these cases are six in which the anticoagulant was shown to act on the second stage of the coagulation process. The two cases of Conley and Hartmann (1) have already been cited. Cohen, Bonnin, and Hicks (13) have studied another such case extensively. Since completion of our studies, Frick (14) has published reports of three cases of "collagen disease" with circulating anticoagulants; two of these patients had systemic lupus erythematosus, while the third was suffering from hypersensitivity to penicillin. To these six, the present series adds five cases and another five probable (mild) cases.
All but one of these patients had systemic lupus. The apparent exception (case 2 of Frick) was a case of penicillin hypersensitivity; in this connection it should be noted that 1) a search for L. E. cells was not made, and 2) Walsh and Zimmerman (15) have reported a lupus-like picture (including L. E. cells) in three cases of penicillin hypersensitivity.
If discussion be limited to patients with clinically apparent clotting disorders, six of seven so far reported with a second-stage anticoagulant had systemic lupus erythematosus. This represents a fairly high degree of specificity (which becomes even higher if one accepts the possible identity of certain penicillin reactions with systemic lupus).
Nine of the ten patients in the present series, however, did not have clinically evident clotting abnormality; the disorder was discovered only because a systematic study was performed on every patient with a positive L. E. cell test. Similar studies have been performed, to date, on 75 control subjects, including normals, and patients with periarteritis nodosa, scleroderma, penicillin reaction, rheumatic fever, rheumatoid arthritis, carcinomatosis, leukemia, and chronic nephritis. A clotting pattern similar to that described here has been found in none of these. This does not establish the specificity of this pattern for systemic lupus erythematosus; the number of controls is too small. However, the finding of this pattern in a patient whose diagnosis is obscure must be considered as evidence for lupus.
The two remaining patients of this series showed the presence of circulating anticoagulant differing slightly from the rest. It is possible that these differences were caused by technical factors; observations on both J. I. and B. L. were unfortunately limited.
Theoretical considerations
Some evidence of the presence of an excess of anticoagulant in the blood appears, in this series, in about 28 per cent of patients with systemic lupus erythematosus, and probably, then, represents a feature of the disease. At least three other interfered with the action of thromboplastin, but not with the formation of thromboplastin. In one patient impaired generation of thromboplastin was found, with no interference with the action of preformed thromboplastin. In the twelfth patient, it could not be determined whether the anticoagulant activity was due to an anti-thromboplastin or an anti-thrombic substance.
The clinical significance of this clotting disorder is not great. In only 3 of the 12 affected patients was hemorrhage a prominent symptom, and in only one could the bleeding be ascribed solely to the anticoagulant activity. However, the type of clotting disorder found in 10 patients in this series seems to have a high degree of specificity for systemic lupus erythematosus.
The possible relationship of these findings to the pattern of abnormal protein metabolism in systemic lupus has been discussed.
